Indeed, when we knocked down RASSF1A in NCI-H1792 human lung cancer cells we saw a decrease in Hippo pathway activation and an increase in TOR pathway activation in the presence of activated Rheb (Figure 3A-3B). This evidence concerns the gene RHEB and lung carcinoma.